医学
拉莫三嗪
鲁拉西酮
莫达非尼
抗抑郁药
重性抑郁障碍
精神科
奎硫平
临床试验
随机对照试验
氟西汀
抗精神病药
精神分裂症(面向对象编程)
内科学
焦虑
心情
癫痫
受体
血清素
作者
Chia Ming Chang,Soichiro Sato,Changsu Han
出处
期刊:CNS Drugs
[Springer Nature]
日期:2013-05-01
卷期号:27 (S1): 21-27
被引量:22
标识
DOI:10.1007/s40263-012-0030-1
摘要
Failure to achieve an adequate response after initial antidepressant treatment in patients with depression is common and remains a clinical challenge. In recent years, some atypical antipsychotic agents have been approved by the US Food and Drug Administration for use in an augmentation strategy for major depressive disorder, and other agents are already in common use in clinical practice. We conducted a search of MEDLINE for relevant studies of augmentation strategies using randomized controlled trials and meta-analyses, and we summarize and discuss the various agents other than atypical antipsychotics. Lithium and thyroid hormone augmentation may improve the response of tricyclic antidepressants but not that of selective serotonin reuptake inhibitors. The efficacy of augmentation with modafinil, buspirone, methylphenidate, folic acid, pindolol and lamotrigine is limited or equivocal. Most of the studies have not focused on treatment-resistant depression (TRD). More trials are needed to help develop evidence-based options for augmentation in TRD.
科研通智能强力驱动
Strongly Powered by AbleSci AI